|
HU228769B1
(en)
*
|
1996-07-24 |
2013-05-28 |
Celgene Corp |
Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha
|
|
US7329670B1
(en)
|
1997-12-22 |
2008-02-12 |
Bayer Pharmaceuticals Corporation |
Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
|
|
US7517880B2
(en)
|
1997-12-22 |
2009-04-14 |
Bayer Pharmaceuticals Corporation |
Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
|
|
US8124630B2
(en)
*
|
1999-01-13 |
2012-02-28 |
Bayer Healthcare Llc |
ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP1140840B1
(en)
*
|
1999-01-13 |
2006-03-22 |
Bayer Pharmaceuticals Corp. |
-g(v)-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
US7351834B1
(en)
|
1999-01-13 |
2008-04-01 |
Bayer Pharmaceuticals Corporation |
ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
EP2298311B1
(en)
|
1999-01-13 |
2012-05-09 |
Bayer HealthCare LLC |
w-Carboxy aryl substituted diphenyl ureas as p38 kinase inhibitors
|
|
EP1466906A1
(en)
*
|
1999-03-12 |
2004-10-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic urea and related compounds useful as anti-inflammatory agents
|
|
TR200102817T2
(tr)
*
|
1999-03-12 |
2002-05-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Antiinflamatuar ajanlar olarak faydalı bileşikler
|
|
US7629360B2
(en)
|
1999-05-07 |
2009-12-08 |
Celgene Corporation |
Methods for the treatment of cachexia and graft v. host disease
|
|
CA2374737C
(en)
*
|
1999-07-09 |
2008-02-12 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Novel process for synthesis of heteroaryl-substituted urea compounds
|
|
ES2292488T3
(es)
|
1999-11-16 |
2008-03-16 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Derivados de la urea, como agentes antiinflamatorios.
|
|
US6822093B2
(en)
|
2000-05-23 |
2004-11-23 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis of heteroarylamine intermediate compounds
|
|
US6635767B2
(en)
*
|
2000-05-23 |
2003-10-21 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis of heteroarylamine intermediate compounds
|
|
US7235576B1
(en)
|
2001-01-12 |
2007-06-26 |
Bayer Pharmaceuticals Corporation |
Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
|
|
MXPA03006749A
(es)
|
2001-02-15 |
2004-05-31 |
Boehringer Ingelheim Pharma |
Proceso para la sintesis de compuestos de urea sustituidos con heteroarilo, utiles como agentes antiinflamatorios.
|
|
EP1375465A4
(en)
|
2001-04-03 |
2006-01-11 |
Eisai Co Ltd |
CYCLOOCTANON DERIVATIVE AND CYCLODECANON DERIVATIVE AND THEIR USE
|
|
JP2005504727A
(ja)
*
|
2001-04-13 |
2005-02-17 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症薬として有用なウレア化合物
|
|
US7371763B2
(en)
|
2001-04-20 |
2008-05-13 |
Bayer Pharmaceuticals Corporation |
Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
|
|
JP2004530690A
(ja)
|
2001-05-16 |
2004-10-07 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
抗炎症性薬剤として有用なジアリールウレア誘導体
|
|
BR0209932A
(pt)
*
|
2001-05-22 |
2004-10-13 |
Neurogen Corp |
Composto ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, preparação farmacêutica embalada, métodos para modular ligação de mch a um receptor de mch e de mvc, para alterar a atividade de transdução de sinal de um receptor de mch em uma célula, para tratar uma doença ou distúrbio associado com a ativação de receptor de mch patogênico obesidade e para determinar a presença ou ausência de receptor de mch em uma amostra, e, uso de um composto
|
|
EP1935885A3
(en)
*
|
2001-05-22 |
2008-10-15 |
Neurogen Corporation |
Melanin concentrating hormone receptor ligands : substituted 1-benzyl-4-aryl piperazine analogues.
|
|
MXPA03010724A
(es)
*
|
2001-05-25 |
2004-03-02 |
Boehringer Ingelheim Pharma |
Compuestos de carbamato y oxamida como inhibidores de la produccion de citocina.
|
|
ATE338035T1
(de)
|
2001-06-05 |
2006-09-15 |
Boehringer Ingelheim Pharma |
1,4-disubstituierte benzokondensierte cycloalkyl harnstoffverbindungen
|
|
US8329924B2
(en)
*
|
2001-06-11 |
2012-12-11 |
Vertex Pharmaceuticals (Canada) Incorporated |
Compounds and methods for the treatment or prevention of Flavivirus infections
|
|
EP2363396A1
(en)
*
|
2001-06-11 |
2011-09-07 |
Virochem Pharma Inc. |
Thiophene derivatives as antiviral agents for flavivirus infection
|
|
ES2274993T3
(es)
|
2001-06-29 |
2007-06-01 |
Ab Science |
Utilizacion de inhibidores de tirosina cinasa para el tratamiento de enfermedades alergicas.
|
|
WO2003003006A2
(en)
|
2001-06-29 |
2003-01-09 |
Ab Science |
New potent, selective and non toxic c-kit inhibitors
|
|
WO2003002105A2
(en)
*
|
2001-06-29 |
2003-01-09 |
Ab Science |
Use of tyrosine kinase inhibitors for treating bone loss
|
|
ATE330608T1
(de)
|
2001-06-29 |
2006-07-15 |
Ab Science |
Die verwendung von n-phenyl-2-pyrimidine-amine derivaten zur behandlung von entzündlichen erkrankungen
|
|
PT1401416E
(pt)
|
2001-06-29 |
2007-02-28 |
Ab Science |
Utilização de inibidores de c-kit para tratar doenças inflamatórias intestinais (dii)
|
|
EP1709965A3
(en)
|
2001-07-11 |
2006-12-27 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediate diseases
|
|
ES2230343T3
(es)
*
|
2001-07-11 |
2005-05-01 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Nueva sintesis de compuestos de heteroarilamina.
|
|
US6603000B2
(en)
|
2001-07-11 |
2003-08-05 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Synthesis for heteroarylamine compounds
|
|
ES2284887T3
(es)
*
|
2001-07-11 |
2007-11-16 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Metodos para tratar enfermedades transmitidas por citocinas.
|
|
MY138086A
(en)
|
2001-09-13 |
2009-04-30 |
Smithkline Beecham Plc |
Novel urea derivative as vanilloid receptor-1 antagonist
|
|
WO2003022273A1
(en)
*
|
2001-09-13 |
2003-03-20 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Methods of treating cytokine mediated diseases
|
|
WO2003032989A1
(en)
*
|
2001-10-18 |
2003-04-24 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
1,4-disubstituted benzo-fused urea compounds as cytokine inhibitors
|
|
US20080108672A1
(en)
*
|
2002-01-11 |
2008-05-08 |
Bernd Riedl |
Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors
|
|
WO2003068229A1
(en)
|
2002-02-11 |
2003-08-21 |
Bayer Pharmaceuticals Corporation |
Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
|
|
DK1478358T3
(da)
*
|
2002-02-11 |
2013-10-07 |
Bayer Healthcare Llc |
Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
|
|
ATE529406T1
(de)
|
2002-02-11 |
2011-11-15 |
Bayer Healthcare Llc |
Aryl-harnstoffe als kinase inhibitoren
|
|
EP1480973B1
(en)
*
|
2002-02-25 |
2008-02-13 |
Boehringer Ingelheim Pharmaceuticals Inc. |
1,4-disubstituted benzofused cycloalkyl urea compounds useful in treating cytokine mediated diseases
|
|
KR20040101398A
(ko)
*
|
2002-04-05 |
2004-12-02 |
베링거 잉겔하임 파르마 게엠베하 운트 코 카게 |
점액 과다분비의 치료방법
|
|
US20030225089A1
(en)
*
|
2002-04-10 |
2003-12-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on anticholinergics and p38 kinase inhibitors
|
|
EP1497278B1
(en)
*
|
2002-04-11 |
2010-05-26 |
Boehringer Ingelheim Pharmaceuticals Inc. |
Heterocyclic amide derivatives as cytokine inhibitors
|
|
US20030236287A1
(en)
*
|
2002-05-03 |
2003-12-25 |
Piotrowski David W. |
Positive allosteric modulators of the nicotinic acetylcholine receptor
|
|
KR100545745B1
(ko)
*
|
2002-06-19 |
2006-01-24 |
주식회사 뉴로테크 |
테트라플루오로벤질 유도체 및 이를 함유하는 급성 및퇴행성 뇌신경계 질환의 예방 및 치료용 약학적 조성물
|
|
AU2003245989A1
(en)
*
|
2002-07-09 |
2004-01-23 |
Boehringer Ingelheim Pharma Gmbh And Co. Kg |
Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases
|
|
US20040044020A1
(en)
*
|
2002-07-09 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors
|
|
WO2004014870A1
(en)
*
|
2002-08-08 |
2004-02-19 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Fluorinated phenyl-naphthalenyl-urea compounds as inhibitors of cytokines involved in inflammatory processes
|
|
US7232828B2
(en)
*
|
2002-08-10 |
2007-06-19 |
Bethesda Pharmaceuticals, Inc. |
PPAR Ligands that do not cause fluid retention, edema or congestive heart failure
|
|
US20040110755A1
(en)
*
|
2002-08-13 |
2004-06-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Combination therapy with p38 MAP kinase inhibitors and their pharmaceutical compositions
|
|
JP2006500365A
(ja)
*
|
2002-08-14 |
2006-01-05 |
ベーリンガー インゲルハイム ファーマシューティカルズ インコーポレイテッド |
p38MAPキナーゼインヒビターを用いた抗凝固及び線維素溶解療法
|
|
US7179836B2
(en)
*
|
2002-09-20 |
2007-02-20 |
Smithkline Beecham Corporation |
Chemical compounds
|
|
US7202259B2
(en)
*
|
2002-11-18 |
2007-04-10 |
Euro-Celtique S.A. |
Therapeutic agents useful for treating pain
|
|
CA2506913A1
(en)
*
|
2002-11-22 |
2004-06-10 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Preparation of aryl intermediates compounds using trialkylmagnesate reagents
|
|
DE60332482D1
(de)
|
2002-12-10 |
2010-06-17 |
Virochem Pharma Inc |
Verbindungen und methoden zum behandeln oder vorbeugen von flavivirus infektionen
|
|
US7144911B2
(en)
*
|
2002-12-31 |
2006-12-05 |
Deciphera Pharmaceuticals Llc |
Anti-inflammatory medicaments
|
|
US7202257B2
(en)
|
2003-12-24 |
2007-04-10 |
Deciphera Pharmaceuticals, Llc |
Anti-inflammatory medicaments
|
|
UY28213A1
(es)
|
2003-02-28 |
2004-09-30 |
Bayer Pharmaceuticals Corp |
Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
|
|
KR101099281B1
(ko)
*
|
2003-03-03 |
2011-12-26 |
어레이 바이오파마 인크. |
p38 억제제 및 그의 사용 방법
|
|
US7135575B2
(en)
*
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
|
BRPI0408248A
(pt)
|
2003-03-12 |
2006-03-01 |
Pfizer Prod Inc |
derivados azabicìclicos de piridiloximetila e de benzisoxazol
|
|
GB2400101A
(en)
*
|
2003-03-28 |
2004-10-06 |
Biofocus Discovery Ltd |
Compounds capable of binding to the active site of protein kinases
|
|
US20070010529A1
(en)
*
|
2003-05-19 |
2007-01-11 |
Kanji Takahashi |
Nitrogenous heterocyclic compounds and medical use thereof
|
|
EP1636585B2
(en)
*
|
2003-05-20 |
2012-06-13 |
Bayer HealthCare LLC |
Diaryl ureas with kinase inhibiting activity
|
|
PL1663978T3
(pl)
*
|
2003-07-23 |
2008-04-30 |
Bayer Healthcare Llc |
Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
|
|
CN1838958A
(zh)
*
|
2003-08-22 |
2006-09-27 |
贝林格尔·英格海姆药物公司 |
治疗慢性阻塞性肺病和肺动脉高血压的方法
|
|
WO2005075455A2
(en)
*
|
2004-01-30 |
2005-08-18 |
Euro-Celtique S.A. |
Methods for making 4-tetrazolyl-4-phenylpiperidine compounds
|
|
US7838524B2
(en)
*
|
2004-04-30 |
2010-11-23 |
Bayer Healthcare Llc |
Substituted pyrazolyl urea derivatives useful in the treatment of cancer
|
|
US7550499B2
(en)
*
|
2004-05-12 |
2009-06-23 |
Bristol-Myers Squibb Company |
Urea antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
SI1761520T1
(sl)
|
2004-06-23 |
2008-10-31 |
Lilly Co Eli |
Inhibitorji kinaze
|
|
US20060035893A1
(en)
|
2004-08-07 |
2006-02-16 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders
|
|
US7767677B2
(en)
|
2004-09-20 |
2010-08-03 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors
|
|
EP1799667B1
(en)
|
2004-09-20 |
2013-03-20 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as therapeutic agents
|
|
EP1804799B1
(en)
|
2004-09-20 |
2013-08-21 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
US7951805B2
(en)
|
2004-09-20 |
2011-05-31 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as mediators of stearoyl-CoA desaturase
|
|
EP2289510A1
(en)
|
2004-09-20 |
2011-03-02 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives for the treatment of diseases mediated by stearoyl-coa desaturase enzymes
|
|
CA2580856A1
(en)
|
2004-09-20 |
2006-03-30 |
Xenon Pharmaceuticals Inc. |
Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
|
|
EP2316458A1
(en)
|
2004-09-20 |
2011-05-04 |
Xenon Pharmaceuticals Inc. |
Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
|
|
US7612200B2
(en)
*
|
2004-12-07 |
2009-11-03 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
WO2006062982A2
(en)
|
2004-12-07 |
2006-06-15 |
Locus Pharmaceuticals, Inc. |
Urea inhibitors of map kinases
|
|
PE20060777A1
(es)
|
2004-12-24 |
2006-10-06 |
Boehringer Ingelheim Int |
Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas
|
|
MX2007008434A
(es)
*
|
2005-01-19 |
2007-07-25 |
Squibb Bristol Myers Co |
Derivados de 2-fenoxi-n-(1,3,4-tiadizol-2il)piridin-3-amina y compuestos relacionados como inhibidores del receptor p2y1 para el tratamiento de trastornos tromboembolicos.
|
|
JP5030947B2
(ja)
*
|
2005-05-13 |
2012-09-19 |
ヴァイロケム・ファーマ・インコーポレーテッド |
フラビウイルス感染の治療及び予防のための化合物及び方法
|
|
WO2006125784A1
(en)
*
|
2005-05-24 |
2006-11-30 |
Laboratoires Serono S.A. |
Tricyclic spiro derivatives as crth2 modulators
|
|
EP2029138A1
(en)
|
2005-06-03 |
2009-03-04 |
Xenon Pharmaceuticals Inc. |
Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
|
|
ATE485269T1
(de)
*
|
2005-06-27 |
2010-11-15 |
Bristol Myers Squibb Co |
C-verknüpfte zyklische antagonisten des p2y1- rezeptors mit eignung bei der behandlung thrombotischer leiden
|
|
WO2007002584A1
(en)
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
Linear urea mimics antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
|
AR056867A1
(es)
*
|
2005-06-27 |
2007-10-31 |
Bristol Myers Squibb Co |
Antagonistas heterociclicos n- enlazados del receptor de p2y1 utiles en el tratamiento de condiciones tromboticas. composiciones farmaceuticas.
|
|
WO2007002634A1
(en)
*
|
2005-06-27 |
2007-01-04 |
Bristol-Myers Squibb Company |
Carbocycle and heterocycle antagonists of p2y1 receptor useful in the treatment of thrombotic conditions
|
|
DE102005037499A1
(de)
*
|
2005-08-09 |
2007-02-15 |
Merck Patent Gmbh |
Pyrazolderivate
|
|
US20070049565A1
(en)
*
|
2005-08-24 |
2007-03-01 |
Neurotech Pharmaceuticals Co., Ltd. |
Combination of cell necrosis inhibitor and lithium for treating neuronal death or neurological dysfunction
|
|
US20070298129A1
(en)
*
|
2005-08-24 |
2007-12-27 |
Neurotech Pharmaceuticals Co., Ltd. |
Compounds and compositions for treating neuronal death or neurological dysfunction
|
|
US7714127B2
(en)
*
|
2005-10-06 |
2010-05-11 |
Boehringer Ingelheim Pharmaceuticals, Inc. |
Process for making heteroaryl amine intermediate compounds
|
|
CA2635888A1
(en)
*
|
2006-01-04 |
2007-07-19 |
Locus Pharmaceuticals, Inc. |
Inhibitors of protein kinases
|
|
WO2007089646A1
(en)
*
|
2006-01-31 |
2007-08-09 |
Array Biopharma Inc. |
Kinase inhibitors and methods of use thereof
|
|
WO2007109434A1
(en)
*
|
2006-03-17 |
2007-09-27 |
Boehringer Ingelheim International Gmbh |
Besylate salt form of 1- (5-tert-butyl-2-p-t0lyl-2h-pyraz0l-3-yl) -3- (4- (6- (morpholin-4-yl-methyl) -pyrid in- 3 -yl) -naphthalen- 1-yl) -urea and polymorphs thereof
|
|
US7960569B2
(en)
*
|
2006-10-17 |
2011-06-14 |
Bristol-Myers Squibb Company |
Indole antagonists of P2Y1 receptor useful in the treatment of thrombotic conditions
|
|
SG176488A1
(en)
*
|
2006-11-15 |
2011-12-29 |
Virochem Pharma Inc |
Thiophene analogues for the treatment or prevention of flavivirus infections
|
|
EP1992344A1
(en)
|
2007-05-18 |
2008-11-19 |
Institut Curie |
P38 alpha as a therapeutic target in pathologies linked to FGFR3 mutation
|
|
KR100852962B1
(ko)
*
|
2007-11-12 |
2008-08-20 |
주식회사 뉴로테크 |
2-하이드록시-5-페닐알킬아미노벤조산 유도체 및 이의 염의제조방법
|
|
AR069650A1
(es)
*
|
2007-12-14 |
2010-02-10 |
Actelion Pharmaceuticals Ltd |
Derivados de aminopirazol como agonistas no peptidicos del receptor alx humano
|
|
BRPI0906473A8
(pt)
|
2008-01-04 |
2016-02-10 |
Intellikine Inc |
Certas entidades químicas, composições e métodos
|
|
US8193182B2
(en)
|
2008-01-04 |
2012-06-05 |
Intellikine, Inc. |
Substituted isoquinolin-1(2H)-ones, and methods of use thereof
|
|
ES2420846T3
(es)
*
|
2008-02-05 |
2013-08-27 |
F. Hoffmann-La Roche Ag |
Nuevas piridinonas y piridazinonas
|
|
CN102341385B
(zh)
*
|
2009-03-09 |
2014-01-15 |
大鹏药品工业株式会社 |
能够抑制前列腺素d合酶的哌嗪化合物
|
|
GB0905955D0
(en)
|
2009-04-06 |
2009-05-20 |
Respivert Ltd |
Novel compounds
|
|
NZ601967A
(en)
|
2010-03-12 |
2015-03-27 |
Omeros Corp |
Pde10 inhibitors and related compositions and methods
|
|
EP2556068B1
(en)
|
2010-04-08 |
2019-01-23 |
Respivert Limited |
P38 map kinase inhibitors
|
|
US8933228B2
(en)
|
2010-06-17 |
2015-01-13 |
Respivert, Ltd. |
Respiratory formulations and compounds for use therein
|
|
EP3238722B1
(en)
|
2011-01-10 |
2019-03-13 |
Infinity Pharmaceuticals, Inc. |
Solid forms of isoquinolinones
|
|
ES2659763T3
(es)
*
|
2011-02-14 |
2018-03-19 |
The Regents Of The University Of Michigan |
Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados
|
|
JP6130383B2
(ja)
|
2011-09-30 |
2017-05-17 |
エンドゥ ファーマシューティカルズ,インコーポレイティド |
ピリジン誘導体
|
|
JP6105594B2
(ja)
|
2011-09-30 |
2017-03-29 |
エンドゥ ファーマシューティカルズ,インコーポレイティド |
癌処置用cyp17阻害剤としてのイミダゾール誘導体
|
|
US8476303B2
(en)
*
|
2011-10-31 |
2013-07-02 |
Florida A&M University Board of Trustees |
N-aminopyrrolylmethyltetrahydropyridines as anti-cancer agents
|
|
US8461179B1
(en)
|
2012-06-07 |
2013-06-11 |
Deciphera Pharmaceuticals, Llc |
Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
|
|
US8828998B2
(en)
*
|
2012-06-25 |
2014-09-09 |
Infinity Pharmaceuticals, Inc. |
Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors
|
|
WO2014033447A2
(en)
|
2012-08-29 |
2014-03-06 |
Respivert Limited |
Kinase inhibitors
|
|
EP2890460B1
(en)
|
2012-08-29 |
2017-02-22 |
Respivert Limited |
Kinase inhibitors
|
|
US9783556B2
(en)
|
2012-08-29 |
2017-10-10 |
Respivert Limited |
Kinase inhibitors
|
|
RU2702908C2
(ru)
|
2012-11-01 |
2019-10-14 |
Инфинити Фармасьютикалз, Инк. |
Лечение злокачественных опухолей с использованием модуляторов изоформ pi3-киназы
|
|
EP2981534B1
(en)
|
2013-04-02 |
2017-07-19 |
Topivert Pharma Limited |
Kinase inhibitors based upon n-alkyl pyrazoles
|
|
EP2981535B8
(en)
|
2013-04-02 |
2021-03-10 |
Oxular Acquisitions Limited |
Urea derivatives useful as kinase inhibitors
|
|
WO2014179734A1
(en)
|
2013-05-02 |
2014-11-06 |
The Regents Of The University Of Michigan |
Deuterated amlexanox
|
|
JP6514703B2
(ja)
|
2013-12-20 |
2019-05-15 |
トピバート ファーマ リミテッド |
キナーゼインヒビターとして有用な尿素誘導体
|
|
WO2015160975A2
(en)
|
2014-04-16 |
2015-10-22 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
NZ630810A
(en)
|
2014-04-28 |
2016-03-31 |
Omeros Corp |
Processes and intermediates for the preparation of a pde10 inhibitor
|
|
NZ716462A
(en)
|
2014-04-28 |
2017-11-24 |
Omeros Corp |
Optically active pde10 inhibitor
|
|
MA40775A
(fr)
|
2014-10-01 |
2017-08-08 |
Respivert Ltd |
Dérivé d'acide 4-(4-(4-phényluréido-naphtalén -1-yl) oxy-pyridin-2-yl) amino-benzoïque utilisé en tant qu'inhibiteur de la kinase p38
|
|
CA2980801A1
(en)
|
2015-04-24 |
2016-10-27 |
Omeros Corporation |
Pde10 inhibitors and related compositions and methods
|
|
CA3003611C
(en)
|
2015-11-04 |
2022-11-01 |
Omeros Corporation |
Solid state forms of a pde10 inhibitor
|
|
WO2017132538A1
(en)
|
2016-01-29 |
2017-08-03 |
The Regents Of The University Of Michigan |
Amlexanox analogs
|
|
AU2017245888B2
(en)
|
2016-04-06 |
2021-05-13 |
Oxular Acquisitions Limited |
Kinase inhibitors
|
|
EP3474856B1
(en)
|
2016-06-24 |
2022-09-14 |
Infinity Pharmaceuticals, Inc. |
Combination therapies
|
|
CN106632403B
(zh)
*
|
2017-01-23 |
2018-09-11 |
牡丹江医学院 |
一种手术用止痛消炎药及其制备方法
|
|
US10364245B2
(en)
|
2017-06-07 |
2019-07-30 |
Chiesi Farmaceutici S.P.A. |
Kinase inhibitors
|
|
WO2019126731A1
(en)
|
2017-12-22 |
2019-06-27 |
Petra Pharma Corporation |
Aminopyridine derivatives as phosphatidylinositol phosphate kinase inhibitors
|
|
CN118903436A
(zh)
|
2018-01-31 |
2024-11-08 |
德西费拉制药有限责任公司 |
治疗肥大细胞增多症的组合疗法
|
|
KR102708177B1
(ko)
|
2018-01-31 |
2024-09-23 |
데시페라 파마슈티칼스, 엘엘씨. |
위장관 기질 종양의 치료를 위한 병용 요법
|
|
IL330104A
(en)
|
2019-03-11 |
2026-08-01 |
Deciphera Pharmaceuticals Llc |
Crystalline forms of rifatinib
|
|
TW202112767A
(zh)
|
2019-06-17 |
2021-04-01 |
美商佩特拉製藥公司 |
作為磷脂酸肌醇磷酸激酶抑制劑之胺基吡啶衍生物
|
|
HRP20260411T1
(hr)
|
2019-08-12 |
2026-05-08 |
Deciphera Pharmaceuticals, Llc |
Ripretinib za liječenje gastrointestinalnih stromalnih tumora
|
|
US12691108B2
(en)
|
2019-08-12 |
2026-07-28 |
Deciphera Pharmaceuticals, Llc |
Methods for treating vascular malformations
|
|
FI4084779T3
(fi)
|
2019-12-30 |
2024-12-16 |
Deciphera Pharmaceuticals Llc |
1-(4-bromi-5-(1-etyyli-7-(metyyliamino)-2-okso-1,2-dihydro-1,6-naftyridin-3-yyli)-2-fluorifenyyli)-3-fenyyliurean koostumuksia
|
|
CN115551496A
(zh)
*
|
2020-03-05 |
2022-12-30 |
詹皮克斯有限公司 |
Stat抑制性化合物和组合物
|
|
US11779572B1
(en)
|
2022-09-02 |
2023-10-10 |
Deciphera Pharmaceuticals, Llc |
Methods of treating gastrointestinal stromal tumors
|
|
CN116987041A
(zh)
*
|
2023-08-02 |
2023-11-03 |
河北科技大学 |
一种转移氢化法制备5-(2-氨基-4-氯苯基)四氮唑的方法
|